PTGES and triple-A syndrome: The concept of reaching the maximum possible efficacy of the mPGES-1 inhibition is also supported by the following observation: There was no further AAA growth observed beyond day 7 in both UK4b-treated groups, while the control group exhibited further disease progression with significant continued aortic dilation (P = 0.4443 [10 mg/kg], P = 0.8842 [20 mg/kg], P = 0.0046 [control]).